CLINICAL_TRIALS
trial_result
· 2024-08-28
Clinical Trial Update: Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First Recurrence [Phase 2]
Summary
Phase 2 trial evaluating pembrolizumab plus SurVaxM for recurrent glioblastoma has completed and results have been posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: David Peereboom | Conditions: Recurrent Glioblastoma | Phase 2 | Status: COMPLETED | Results posted: 2024-08-28